A study of more than 100,000 urban commuters in China suggests that walking or cycling to work can lower people’s risk of ischemic heart disease (IHD) and stroke, even when factoring in the “rather serious air pollution” in the country.

The FDA on Oct. 15 issued a warning letter to India-based Torrent Pharmaceuticals, targeting the drug company as one of the primary contributors to the onslaught of BP drug recalls in the past year.

A study of thousands of individuals in Canada suggests the use of angiotensin receptor blockers—as opposed to ACE inhibitors—could be linked to an increased risk of suicide and poor mental health.

Consumer watchdog group U.S. PIRG is criticizing the FDA for “missing their timeline” to review potentially carcinogenic blood pressure medications like losartan, valsartan and irbesartan, arguing the agency needs to step up its efforts to ensure pharmaceutical companies are distributing safe drugs.

The New York City Department of Health and Mental Hygiene has expanded its Health Bucks program to allow pharmacists to “prescribe” produce to low-income residents with high blood pressure.

A combo of cryoballoon ablation and novel oral anticoagulants might be a more effective treatment route than standard care for obese AFib patients, who, according to an Oct. 4 study, are less likely to benefit from traditional catheter ablation in the long-term.

Low birth weight is associated with poorer health outcomes—including CVD—later in life, according to a study out of West Virginia University.

An updated meta-analysis centered around the role marine omega-3 supplementation in CVD prevention suggests there may be a use for fish oil in cardiovascular medicine after all.